UNITY Biotechnology Announces Appointment of Lynne Sullivan as Chief Financial Officer
August 31 2020 - 4:05PM
UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company
developing therapeutics to extend healthspan by slowing, halting or
reversing diseases of aging, today announced the appointment of
Lynne Sullivan to the permanent role of chief financial officer,
effective September 1, 2020.
“Lynne is an incredibly talented senior finance executive with
deep biotech and pharmaceutical industry experience and has already
played an impactful role at UNITY over the past several months as
she became interim CFO,” said Anirvan Ghosh, Ph.D., chief executive
officer of UNITY. “Lynne’s experience across corporate finance and
business development functions will be key to UNITY’s future
success. Having worked with Lynne previously, I know that she will
be an outstanding member of our executive team as we redouble our
efforts to develop a new class of therapeutics to slow, halt or
reverse diseases of aging."
Lynne Sullivan brings more than 20 years of experience
working in the pharma and biotech industry. Ms.
Sullivan worked at Biogen for over 10 years, serving as senior
vice president of finance with global responsibility for corporate
finance, financial planning and analysis and corporate
tax. Ms. Sullivan is a member of the board of directors
of four publicly traded biopharmaceutical companies, Inozyme
Pharma, Solid Biosciences, resTORbio and BiomX, and most recently
served as the chief financial officer for Compass
Therapeutics. She received an M.S. in taxation from Bentley
University and a B.S.B.A. from Suffolk
University. Ms. Sullivan was a Certified Public
Accountant for over 20 years.
About UNITYUNITY is developing a new class of
therapeutics to slow, halt or reverse diseases of aging. UNITY's
initial focus is on creating medicines to selectively eliminate or
modulate senescent cells and thereby provide transformative benefit
in age-related diseases, such as osteoarthritis, eye diseases,
neurological diseases and pulmonary diseases. More information is
available at www.unitybiotechnology.com or follow us
on Twitter.
Forward-Looking Statements
This press release contains forward-looking statements including
statements related to the potential for UNITY to develop
therapeutics to extend healthspan. These statements involve
substantial known and unknown risks, uncertainties and other
factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from the
information expressed or implied by these forward-looking
statements, including the risk that the COVID-19 worldwide pandemic
may continue to negatively impact the development of preclinical
and clinical drug candidates, including delaying or disrupting the
enrollment of patients in clinical trials, risks relating to the
uncertainties inherent in the drug development process and risks
relating to UNITY’s understanding of senescence biology. We may not
actually achieve the plans, intentions or expectations disclosed in
our forward-looking statements, and you should not place undue
reliance on our forward-looking statements. Actual results or
events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements we make.
The forward-looking statements in this press release represent our
views as of the date of this release. We anticipate that subsequent
events and developments will cause our views to change. However,
while we may elect to update these forward-looking statements at
some point in the future, we have no current intention of doing so
except to the extent required by applicable law. You should,
therefore, not rely on these forward-looking statements as
representing our views as of any date subsequent to the date of
this release. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of the Company in general, see UNITY’s
most recent Quarterly Report on Form 10-Q for the quarter ended
June 30, 2020, filed with the Securities and Exchange Commission on
July 31, 2020, as well as other documents that may be filed by
UNITY from time to time with the Securities and Exchange
Commission.
This press release concerns drug candidates that are under
clinical investigation and which have not yet been approved for
marketing by the U.S. Food and Drug Administration. They are
currently limited by Federal law to investigational use, and no
representation is made as to their safety or effectiveness for the
purposes for which they are being investigated. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
Investors
Endurance Advisors
Mike Zanoni
mzanoni@enduranceadvisors.com
Media
Canale Communications
Jason Spark
jason@canalecomm.com
UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Mar 2024 to Apr 2024
UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Apr 2023 to Apr 2024